The type I interferon response protects cells against invading viral pathogens. The cellular factors that mediate this defence are the products of interferon-stimulated genes (ISGs). Although hundreds of ISGs have been identified since their discovery more than 25 years ago [1] [2] [3] , only a few have been characterized with respect to antiviral activity. For most ISG products, little is known about their antiviral potential, their target specificity and their mechanisms of action. Using an overexpression screening approach, here we show that different viruses are targeted by unique sets of ISGs. We find that each viral species is susceptible to multiple antiviral genes, which together encompass a range of inhibitory activities. To conduct the screen, more than 380 human ISGs were tested for their ability to inhibit the replication of several important human and animal viruses, including hepatitis C virus, yellow fever virus, West Nile virus, chikungunya virus, Venezuelan equine encephalitis virus and human immunodeficiency virus type-1. Broadly acting effectors included IRF1, C6orf150 (also known as MB21D1), HPSE, RIG-I (also known as DDX58), MDA5 (also known as IFIH1) and IFITM3, whereas more targeted antiviral specificity was observed with DDX60, IFI44L, IFI6, IFITM2, MAP3K14, MOV10, NAMPT (also known as PBEF1), OASL, RTP4, TREX1 and UNC84B (also known as SUN2). Combined expression of pairs of ISGs showed additive antiviral effects similar to those of moderate type I interferon doses. Mechanistic studies uncovered a common theme of translational inhibition for numerous effectors. Several ISGs, including ADAR, FAM46C, LY6E and MCOLN2, enhanced the replication of certain viruses, highlighting another layer of complexity in the highly pleiotropic type I interferon system.
To identify novel antiviral effectors in the type I interferon (IFN) system, we developed a cell-based assay to determine the effects of hundreds of ISG products on viral replication. The assay relied on a bicistronic lentiviral vector co-expressing an ISG and the red fluorescent protein TagRFP ( Fig. 1a and Supplementary Fig. 1 ). ISG-TagRFP-expressing cells were challenged with a green fluorescent protein (GFP)-expressing virus, and viral replication within the TagRFP-positive population was quantified by fluorescence-activated cell sorting (FACS) (Fig. 1b) . In pilot experiments, 11 ISGs (PSMB8, PSMB9, IFI6, GBP1, IFITM3, MX1, PLSCR1, RTP4, CCDC75, IFIT3 and IFI27) and two control luciferase genes, from Photinus pyralis (Fluc) and Gaussia princeps (Gluc), were tested for the ability to inhibit vesicular stomatitis virus (VSV) and yellow fever virus (YFV) in STAT1-deficient human (STAT1 2/2 ) fibroblasts or in human hepatoma (Huh-7) cells. STAT1 2/2 fibroblasts produce IFN but do not respond to IFN 4 , whereas Huh-7 cells respond to IFN but are not robust producers of IFN 5 . Inhibition was assessed quantitatively by FACS ( Fig. 1c ) and qualitatively by fluorescence microscopy (Supplementary Fig. 1c ). IFI6 and MX1 showed specificity for YFV and VSV, respectively ( Supplementary Fig. 1d ). Both viruses were inhibited by IFITM3, which also suppresses influenza A virus, West Nile virus (WNV) and dengue virus 6 . These results demonstrate the utility of this screening platform and suggest its potential for uncovering antiviral ISGs that target divergent virus families.
To conduct a large-scale antiviral ISG screen, we analysed published microarray data sets from IFN-treated cells or tissues, and we established inclusion criteria 1, [7] [8] [9] [10] [11] [12] [13] [14] [15] (Supplementary Table 1 ). We compiled a list of 389 ISGs, inserted each into the bicistronic lentiviral vector and produced high-titre lentiviral stocks (Methods). Approximately 50 of these lentiviral stocks failed to mediate high-level transduction of target cells ( Supplementary Fig. 2a ), perhaps resulting from ISG-mediated toxicity, auto-downregulation of the internal ribosome entry site (IRES)-driven TagRFP expression, poor packaging of the vector genome or activity against the human immunodeficiency virus 1 (HIV-1)-based vector. We consider that the last possibility is likely because several known antiretroviral genes-EIF2AK2 (also known as PKR), APOBEC3G, BST2 (also known as tetherin) and MOV10-were included in this subset [16] [17] [18] . The potential cytotoxicity of ISG overexpression was inferred from FACS-based cell counts ( Supplementary Fig. 3a ) and validated for a number of genes by luminescence-based cell viability assay ( Supplementary Fig. 3b ). Although two genes were toxic (CDKN1A and TNFRSF10A), most ISGs did not strongly affect cell viability.
The lentivirus-expressed ISG collection was screened for inhibition of hepatitis C virus (HCV) expressing YPet-GFP ( Supplementary Fig.  4 ) in Huh-7.5 cells, a RIG-I-defective derivative of Huh-7 cells, at 48 h and 72 h after infection. Data are presented as a normal distribution ( Fig. 1d ) or dot plots ( Fig. 1e ). Most genes inhibited HCV infection to some extent, with the mean (z score 5 0) level of inhibition being 20%. Four genes (MDA5, RIG-I, IRF1 and IRF7) had z scores of less than 23.0, whereas 53 genes had z scores between 21.0 and 23.0 (Supplementary Tables 2 and 3 ). At 72 h after infection, HCV replication approached a maximum ( Supplementary Fig. 4d ), and the overall profile of ISGs that had antiviral activity was more constricted (Fig. 1e ), probably reflecting the ability of the virus to overcome inhibition. Transient transfection was used to screen the subset of ISGs that were poorly expressed following lentiviral transduction, and several genes (including DDX60, MOV10 and MS4A4A) were found to have anti-HCV activity ( Supplementary Fig. 5 ). To investigate the effect of the host cell environment on ISG activity, we rescreened HCV in a lesspermissive cell type (Huh-7) 19 . The strongest effectors were consistently active in both cell lines ( Fig. 1e and Fig. 2a ), and several additional genes (including MAP3K14 and SLC1A1) inhibited HCV replication to a greater extent in Huh-7 cells than in Huh-7.5 cells (z score less than 22.0; Supplementary Table 4 ). Taken together, these data suggest that there are at least two categories of anti-HCV ISGs: strong inhibitors that probably feed back into IFN-mediated signalling pathways or other signalling pathways, and modest inhibitors that may have targeted effector functions.
We also screened the ISG collection against other medically important viruses from three families: Flaviviridae, YFV and WNV; Togaviridae, chikungunya virus (CHIKV) and Venezuelan equine encephalitis virus (VEEV); and Retroviridae, HIV-1 ( Fig. 2a ). We assayed YFV, WNV, VEEV and CHIKV in STAT1 2/2 fibroblasts and HIV-1 in MT-4 cells (a human T lymphotrophic virus I (HTLV-I)transformed T-cell line). Global ISG inhibition profiles were similar for all viruses, with 10-25 genes having z scores of 21.5 or lower ( Fig. 2a and Supplementary Tables 7-10). YFV was also screened in Huh-7 cells ( Supplementary Fig. 6a ), and this screen yielded fewer hits, with five genes showing a z score below 21.5 ( Supplementary Tables 5  and 6 ). The strongest hits in Huh-7 cells (HPSE, IRF1, IRF7, IFITM3 and IFI6) were also among the top inhibitors in STAT1 2/2 fibroblasts, suggesting that these effectors function independently of cell type. Differences in data between the two cell lines may be due to higher levels of YFV replication in Huh-7 cells ( Supplementary Fig. 6b ) and/ or increased ISG expression in STAT1 2/2 fibroblasts ( Supplementary  Fig. 2b ). These differences indicate that STAT1 2/2 fibroblasts provide a more sensitive environment for detecting ISG-mediated inhibition.
The strongest antiviral ISGs from each primary screen were validated by generating independent lentiviral stocks and measuring inhibition from at least eight replicates ( Fig. 2b ). Forty-five hits (ISGs) were confirmed to reduce viral replication significantly compared with a control gene (Fluc) (P , 0.001 for 44 genes and P , 0.05 for 1 gene), and five genes were false positives. Further validation was conducted for a subset of ISGs. Inhibition of YFV by IFI6, IFITM3 and RTP4 was dose dependent ( Supplementary Fig. 7a ), and both IFITM3 and IFI6 inhibited production of the parental, non-GFP-expressing, virus (YFV-17D) ( Supplementary Fig. 7b , c). We also measured the effects of anti-HCV ISGs when they were introduced after infection with HCV ( Supplementary Fig. 8 ). In contrast to the 20-70% range in inhibition observed when ISGs were expressed before infection ( Fig. 2b ), ISG expression after infection affected replication by either less than 20% (for DDIT4, NT5C3, IFI44L, MAP3K14 and IRF2) or more than 80% (for IRF7, IRF1, MDA5 and RIG-I). Only one gene, OASL, showed an intermediate phenotype ( Supplementary Fig. 8 ).
These data demonstrate that the overexpression platform is highly reliable for identifying antiviral ISGs and is sensitive enough to detect even modest levels of inhibition both before and after infection.
In the primary screens, several genes enhanced viral replication ( Fig. 2a ). This activity was confirmed for six of these (ADAR, APOBEC3A, FAM46C, IDO1, LY6E and MCOLN2) by testing against YFV, WNV, VEEV and CHIKV in STAT1 2/2 fibroblasts ( Fig. 2d ). For most of these six genes, we found an increase in the number of YFV-or VEEV-infected cells, whereas the replication of WNV and CHIKV was largely unaffected. Consistent with the primary YFV screen, LY6E conferred a striking 75% increase in infection frequency ( Fig. 2d and Supplementary Fig. 9 ), a phenotype that may correlate with studies implicating LY6E in the susceptibility of chickens to Marek's disease virus 20 and of mice to adenovirus 21 . Analysis of mean GFP intensity in infected cells revealed that ADAR significantly enhanced the replication of all viruses against which it was tested ( Supplementary Fig. 9 ). Thus, in contrast to LY6E, which caused an increase in the number of infected cells, ADAR affected the level of replication within the cell. ADAR encodes an RNA-specific adenosine deaminase that has been reported to stimulate HIV-1 infection through RNA editing 22 . ADAR also promotes infection with measles virus 23 , supporting a pan-viral mechanism of enhancement.
The screening and validation data uncovered both broad-acting effectors and specific effectors. IRF1, which encodes a transcription factor in the IFN pathway, inhibited all viruses against which it was tested ( Fig. 2c ), even in a STAT1 2/2 background. Given that there are more than 200 IRF1-binding sites in the human genome 24 , our data suggest that IRF1 activates a unique antiviral program. Indeed, microarray analysis of IRF1-transduced Huh-7 cells or STAT1 2/2 fibroblasts showed that numerous ISGs were induced ( Supplementary  Fig. 10 ), but no IFN genes were upregulated (data not shown). Most genes that were induced greater than threefold in Huh-7 cells (P , 0.05) were similarly upregulated in STAT1 2/2 fibroblasts, and both of these cell lines had a subset of uniquely regulated transcripts. Several of our antiviral hits were among the IRF1-induced transcripts, supporting the observation that the effector mechanisms of IRF1 partly overlap with those of IFN but do not require IFN activity. The genes C6orf150, HPSE, RIG-I, MDA5, IFITM3, IRF7 and NAMPT were also active against more than one viral species, whereas other genes showed more restricted antiviral specificities. Gene ontology analysis 
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was performed to classify the confirmed antiviral ISGs. Compared with the entire ISG collection, the validated list had a significant over-representation of three molecular functions (nucleic acid binding, hydrolase activity and helicase activity) and three biological processes (signal transduction, transcription initiation and small molecule transport) ( Supplementary Fig. 11 and Supplementary Table 11 ).
The identification of modest to strong virus inhibitors suggests that an effective IFN response requires the combinatorial action of numerous ISGs. This hypothesis was initially proposed from microarray 1 and gene knockout studies 25 , but there are limited experimental data showing combinatorial ISG function. To determine whether the effects of ISGs are greater when the genes are expressed in combination, selected hits from the HCV, HIV-1 and YFV screens were tested in all of the possible two-gene pairs ( Fig. 3a and Supplementary Fig. 12 ). ISG effects were generally additive, with some combinations reducing replication by greater than 90%, an efficacy similar to moderate doses of IFN ( Fig. 3b-e ). For YFV, when one inhibitory and one enhancing ISG were tested together (for example, C6orf150 and MCOLN2), the magnitude of viral replication was more strongly influenced by the inhibitory gene.
To probe the mechanisms of antiviral action, selected ISGs were tested for the ability to inhibit various stages of the viral life cycle.
Using HCV pseudoparticles, none of the eight anti-HCV ISGs significantly impaired virus entry into Huh-7 cells ( Supplementary Fig. 13a ). By contrast, analysis of subgenomic HCV replicons expressing the Gluc reporter showed that all ISGs that were tested inhibited primary translation by 25-70% at 4 h post transfection (Fig. 4a, b and Supplementary Fig. 13b, c) . Notably, the strongest translational inhibitors were also the most potent suppressors of replication, as measured by Gluc protein production at 72 h ( Fig. 4b) and confirmed by quantifying the HCV genome copy number ( Supplementary Fig. 13d ). The finding that each of the eight genes, which have a range of predicted molecular functions ( Supplementary Table 11 ), blocked initial translation suggests the importance of this host cell strategy for suppressing HCV. IRF1 and RIG-I were also associated with a kinetic delay in the onset of replication, suggesting that there are multiple possible stages at which the HCV life cycle can be blocked by these effectors.
We also investigated the mechanism of action of C6orf150, which encodes a putative nucleotidyltransferase 26 and contains a Mab-21 domain but is otherwise uncharacterized. Because C6orf150 inhibited the alphaviruses CHIKV and VEEV, we tested it against the related virus Sindbis virus (SINV). C6orf150 inhibited the replication of GFP-expressing SINV (Fig. 4c ) and infectious virus production by HIV MX2  IFITM2  CD74  IRF1   RTP4  C6orf150  IRF1  TNFRSF10A  IFI6  HPSE   LY6E   MCOLN2   FAM46C   IDO1  APOBEC3A   ADAR  IDO1   MDA5  RIG-I  C6orf150  HPSE  IRF1   MDA5  NAMPT  HPSE  RIG-I  C6orf150  IRF1   P2RY6  SLC25A28  SLC15A3  C6orf150  UNC93B1  IRF1   IRF7  MAP3K14  RIG-I  IRF2  IRF1   APOBEC3A Data are presented as box and whisker plots: grey boxes extend from the 25th to the 75th percentile, with a black line at the population median; whiskers extend to show the highest and lowest values (n 5 8 for HCV and n 5 9 for other viruses). Statistical significance was determined by one-way ANOVA (***, P , 0.001; **, P , 0.01; *, P , 0.05; NS, not significant). c, Frequency of validated antiviral ISG activity across six screens.
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non-GFP-expressing SINV (Fig. 4d ). We next assessed the activity of C6orf150 against a Fluc-expressing temperature-sensitive virus, SINV(ts6), which is competent for primary translation but does not replicate at non-permissive temperatures (Methods). SINV(ts6) was susceptible to inhibition by C6orf150 (Fig. 4e) , indicating an early viral translation block. Interestingly, the pan-viral inhibitor IRF1 also blocked SINV(ts6) translation, suggesting that this effector mechanism is reinforced by IFN-induced transcriptional factors. Similar to the HCV life-cycle studies, the importance of translational inhibition is highlighted by a corresponding reduction in replication of wildtype SINV-Fluc (Fig. 4f ).
The antiviral effects of type I IFN were first described more than 50 years ago 27 . Since then, great strides have been made in understanding the mechanisms that govern virus-mediated IFN production, IFN gene regulation and IFN-mediated signalling 28, 29 . Insight into downstream IFN effector mechanisms, however, has largely been limited to a select group of ISGs, probably because of the difficulties involved in systematically overexpressing hundreds of genes. With the strategy presented here, we have overcome these technical barriers and identified multiple novel antiviral ISGs, many of which target early steps in the viral life cycle. Combined with our previous understanding of well-known antiviral effectors such as PKR (which is encoded by EIF2AK2) and IFIT proteins, life-cycle stage characterization of these newly identified ISGs suggests that the IFN system may use multiple strategies to engender a single outcome such as translational inhibition. Clinically, IFN is used to treat several viral infections and is a principle component of HCV treatment. Given the clinical side effects of IFN treatment, and the natural ability of viruses to thwart its activity 30 (n 5 3) . c-f, Statistical significance was determined by one-way ANOVA (***, P , 0.001; **, P , 0.01). p.f.u., plaque-forming units.
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of individual ISGs may be a preferable therapeutic strategy. Further insight into the biochemical mechanisms of these effectors may provide a platform for the development of alternatives to IFN-based therapies.
METHODS SUMMARY
To screen ISGs for antiviral activity, we obtained sequence-validated ORFEXPRESS ISG shuttle clones (GeneCopoeia) and used Gateway technology to move genes into a lentiviral vector co-expressing TagRFP (Evrogen). Lentiviruses were packaged in 293T cells by using established techniques (Methods). Target cell lines were transduced with the lentiviral ISG stocks for 2-3 days and then infected with a GFP-expressing virus at a multiplicity of infection of approximately 0.5-1.0. Cells were collected in Accumax Cell Aggregate Dissociation Medium (eBioscience), fixed in 1% paraformaldehyde and analysed on an LSRII-HTS flow cytometer (BD Biosciences). To quantify viral replication, RFP 1 cells were gated, and the number of GFP 1 cells in the RFP 1 population was determined. Replication levels were normalized to controls (Fluc or Gluc) to obtain z scores. In some cases, we measured replication levels by determining mean GFP fluorescence intensity in the RFP 1 GFP 1 population. For all ISG hit validation experiments, we generated lentiviral stocks that were independent from the primary screening preparations. To determine statistical significance, we used one-way analysis of variance (ANOVA) for at least eight replicates. For HCV lifecycle experiments, ISG-expressing Huh-7 cells were infected with genotype 1b HCV pseudoparticles or transfected with in vitro-transcribed HCV subgenomic RNA expressing Gluc. For SINV life-cycle experiments, ISG-expressing STAT1 2/2 fibroblasts were infected with SINV variants, and cells were monitored for GFP levels by FACS, for Fluc levels by reporter assay and for virus production by plaque assay on BHK-J cells. Cell viability and reporter gene assays for Gluc and Fluc were performed with commercially available kits (Promega). Gene ontology analysis was performed using the PANTHER Classification System (http:// www.pantherdb.org). Microarray studies were performed on total RNA collected from Fluc-expressing or IRF1-expressing cells using BeadArray technology (Illumina). collected from transduced cells 48 h later using an RNeasy Mini Kit (Qiagen). RNA amplification was carried out with a MessageAmp Premier RNA Amplification Kit (Applied Biosystems). Total RNA (200 ng) was used to synthesize the first strand of cDNA using ArrayScript reverse transcriptase and an oligo(dT) primer bearing a T7 promoter. The single-stranded cDNA was then converted into double-stranded DNA by DNA polymerase I in the presence of E. coli RNase H and DNA ligase. The double-stranded DNA served as a template for in vitro transcription in a reaction containing biotin-labelled UTP, unlabelled NTPs and T7 RNA Polymerase. The amplified, biotin-labelled antisense RNA was purified, and its quality was assessed using the 2100 Bioanalyzer (Agilent) and the RNA 6000 Nano kit (Agilent). Antisense RNA (750 ng in 5 ml) was mixed with 10 ml of hybridization reagents and heated at 65 uC for 10 min. After cooling to room temperature, 15 ml hybridization solution was applied to a HumanHT-12 v4 chip (Illumina). The chip was incubated for about 18 h at 58 uC. After washing and staining with streptavidin-Cy3, the chip was scanned using a BeadArray Reader (Illumina). The scanning was done using a standard DirectHyb Gene Expression protocol with the following settings: Factor 5 1, PMT 5 587 and Filter 5 100%. The raw data were extracted using BeadStudio software (Illumina) without normalization. Data were analysed using GeneSpring software with global normalization. Student's unpaired t-test was used to determine statistical significance.
